Conexeu Sciences

One formulation, applied to veterinary medicine. CXU is designed to mimic tissue ECM and support durable closure with less scarring. Investigational device.

A potential new category in soft-tissue restoration. B.R.E.A.S.T. applies the CXU platform to breast reconstruction beyond implants. Preclinical stage.

Bioregeneration explores how the body's own regenerative processes may restore tissue structure and function. Conexeu is evaluating its CXU ECM platform. Investigational.

How CXU works — a structural extracellular matrix designed to support cell migration, vascularization and tissue integration. Preclinical evidence and patents.

Conexeu Completes 12-Month Preclinical P.R.O.O.F Study, Supporting Its Intended Move Into the $11 Billion Medical Aesthetics Market as a Platform¹

Architecture is the shaping of space for human life — thoughtful, intentional, purposeful. Conexeu applies the same discipline to the body itself.

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU Platform

Press releases, company news and commentary from Conexeu Sciences on bioregeneration, the CXU platform and the regenerative tissue market.

Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution

Conexeu’s B.R.E.A.S.T. was developed using the Company’s proprietary CXU regenerative tissue platform to support gradual tissue remodeling

Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027.

Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company’s planned FDA 510(k) submission in the first quarter of 2027

CEO Miles Harrison on why the CXU platform is designed to create a biological scaffold the body can rebuild into, rather than replacing tissue with fillers or implants.

An introduction to Conexeu Sciences and its patented bioregenerative extracellular matrix platform, CXU, built on more than a decade of university research.

Conexeu Sciences is a preclinical-stage regenerative tissue platform company. The page introduces its leadership, board, and medical advisory team.

A message from President and CEO Miles Harrison on what Architecting Bioregeneration means for the company and the patients it aims to serve.

Conexeu Sciences provides contact information for inquiries about the CXU platform, partnerships, licensing, and media.

The page offers information on topics including bioregeneration, ECM science, CXU, aesthetics, wound care, oral health, animal health, and 3D tissue.

Conexeu Sciences is developing CXU, an investigational bioregenerative ECM designed as a structural scaffold the body's own cells migrate into and remodel.

Conexeu Sciences introduces a human collagen initiative targeting regenerative aesthetics, leveraging rising demand fueled by GLP-1 treatments. The company focuses on tissue restoration solutions amid growing interest in non-surgical cosmetic interventions. This move aligns with broader trends in biotech-driven aesthetic innovations.

Nov 2026GlobeNewswireNews article

Conexeu Sciences closes a **$5 million private placement**, primarily funded by existing shareholders, management, and directors. The company, focused on its **CXU™ investigational tissue-restoration platform**, holds **$250,000** of subscriptions in escrow pending regulatory approval. The funding supports its preclinical-stage medical device and regenerative medicine development.

Oct 2026Conexeu Sciences, Inc.News article

Conexeu Sciences is progressing its **Ten Minute Tissue™**, a wound care device, toward a **U.S. FDA 510(k) submission**. The company, specializing in regenerative medicine, updates its regulatory and manufacturing readiness for this lead product. Ten Minute Tissue™ is part of its **CXU™ investigational tissue-restoration platform**, currently in preclinical development.

Oct 2026MarketScreenerNews article

Conexeu Sciences identifies a new category in medical aesthetics centered on regenerative approaches. The company highlights emerging research shifting focus toward tissue regeneration and repair mechanisms. This trend aims to redefine traditional aesthetic treatments by integrating advanced biological therapies.

Aug 2026GlobeNewswireNews article